Chemical Structure (Biktarvy 01)
Biktarvy Tablet
Product Images NDC 61958-2501
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Biktarvy (NDC 61958-2501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Biktarvy 02)
Chemical Structure (Biktarvy 03)
Principal Display Panel (50 mg/200 mg/25 mg Tablet Bottle Label)
Biktarvy tablets contain bictegravir, emtriciabine, and tenofovi alafenamide that work together to treat certain viral infections. Each tablet has 50 mg of bictegravir, 200 mg of emtriciabine, and 25 mg of tenofovir alafenamide. They are stored below 30°C (66°F) and should be kept in their original container. Biktarvy tablets are available in a pack of 30 tablets, and the dosage and administration information can be found in the package insert. It is manufactured for Gilead Sciences, Inc. and made in Germany.*
Biktarvy 05
The text describes the dosage information for a medication called Biktarvy. Each tablet contains 30mg of bictegravir, 120mg of emtricitabine, and 15mg of tenofovir alafenamide. The medication should be stored below 30°C and dispensed only in the original container. The recommended dose is 1 tablet a day. The manufacturer is Gilead Sciences Inc. It contains a warning not to be taken with certain medicines and should be kept out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
